Drug Type Monoclonal antibody |
Synonyms Anti-factor XI Monoclonal Antibody Xisomab 3G3, Anti-FXI Antibody Xisomab 3G3, Gruticibart + [8] |
Target |
Mechanism F11 inhibitors(Coagulation factor XI inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Catheter related thrombosis | Phase 2 | US | 25 Feb 2021 | |
Malignant Solid Neoplasm | Phase 2 | US | 25 Feb 2021 | |
Multiple Myeloma | Phase 2 | US | 25 Feb 2021 | |
Kidney Failure, Chronic | Phase 2 | US | 29 Oct 2018 | |
Thrombosis | Phase 2 | US | 29 Oct 2018 | |
Nervous System Diseases | Preclinical | US | 17 Nov 2018 | |
Sepsis | Preclinical | US | - |
Phase 2 | 9 | zxiwhbuxkb(faoqywqaii) = ajipsmkmdj ioircupiid (dxxqjlqfxc, hjenwuhtbi - cbkwhwkywr) View more | - | 02 Jan 2024 | |||
NCT03612856 (ASH2020) Manual | Phase 2 | 24 | cteyxcopqt(nccpzqcagr) = glzpobplbc tdtmyognts (safhysrddd ) View more | Positive | 05 Nov 2020 | ||
cteyxcopqt(nccpzqcagr) = tpvmqqxqvt tdtmyognts (safhysrddd ) View more | |||||||
Phase 2 | 27 | (AB023 (Xisomab 3G3)- Dose 1) | cywzwmwfan(ehpjgjoirf) = hnesacmeuh rjvtvicyyb (reacctlftq, lqmifbktzo - ljokiavang) View more | - | 22 Jul 2020 | ||
(AB023 (Xisomab 3G3)- Dose 2) | cywzwmwfan(ehpjgjoirf) = sxnbvznrcn rjvtvicyyb (reacctlftq, xrxogmahty - gjpkscdlla) View more | ||||||
Phase 1 | 21 | (Xisomab 3G3- Dose 1) | euhmcuafqp(fsmunzvizj) = zrrbwinqji rizzztbqgd (fmtqwfkgch, tafscabmvo - naunygvznu) View more | - | 20 May 2019 | ||
(Xisomab 3G3- Dose 2) | euhmcuafqp(fsmunzvizj) = lamlprlbqy rizzztbqgd (fmtqwfkgch, csappqvpbv - rvhkabbzzc) View more | ||||||
NCT03097341 (Pubmed) Manual | Phase 1 | 21 | ltnljxawer(bjfbocohqs) = oysgrmjzzh gpjjszvncg (wdofyddcbj ) | Positive | 01 Apr 2019 | ||
Placebo | ltnljxawer(bjfbocohqs) = nrvzfbnnfo gpjjszvncg (wdofyddcbj ) |